EGFR and nasopharyngeal carcinoma: For example, in EBV-associated NPC, some clinically important mutations with potential targeted therapies including PIK3CA, EGFR, FGFR1, and BRCA/ATM are uncommon; fusion genes such as FGFR3 are also uncommon.